Muvalaplin for heart disease in people with high lipoprotein(a)
Part of Heart & circulation clinical trials.
This study tests a new medicine called muvalaplin that lowers a specific type of cholesterol linked to heart disease. It aims to see if muvalaplin can reduce the risk of future heart attacks, strokes, or related procedures in people with high levels of this cholesterol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high level of a specific kind of cholesterol called lipoprotein(a) — at least 175 nanomoles per liter.
- You have had a heart attack, stroke, or a procedure to open blocked arteries within the last 10 years, OR you have a condition that puts you at high risk for a first heart attack or stroke (like blocked arteries in your heart, neck, or legs, a high calcium score in your heart arteries, or kidney problems with diabetes).
- You have not had a heart attack, stroke, or major heart surgery in the last 3 months.
- Your blood pressure is under control (not too high).
- You do not have severe heart failure or severe kidney disease.
- You have not had cancer (other than some skin cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs designed to lower lipoprotein(a)—a type of cholesterol particle linked to heart disease—in people whose levels remain high despite taking statins (cholesterol-lowering medications). The goal is to see if these drugs can safely reduce this risk factor.
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
This study tests an experimental oral medication, SAL0137, to see if it can lower Lp(a) levels, a type of fat in the blood linked to heart disease. It may help people who have high Lp(a) and are at increased risk for heart attacks or strokes.
This study tests an investigational medicine given by injection to lower Lp(a), a type of fat linked to heart disease. It may help people with high Lp(a) who already have heart problems or are at increased risk.
This study tests an oral medication called HRS-5346 to see if it can lower a type of fat in the blood called lipoprotein(a), which is linked to heart disease. If you have high Lp(a) and are at risk for heart problems, this trial may help reduce that risk.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.